Breaking News

CordenPharma Increases Lipid Manufacturing Capacity

Investment at Chenôve facility in France will support mRNA vaccine strategy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CordenPharma, a full-service contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, unveiled a major investment project to increase lipid manufacturing capacity at its CordenPharma Chenôve facility, near Dijon, France. This decision was a result of the increased demand to supply millions of patients with life-enhancing or life-saving medicines based on mRNA technology. After the successful compl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters